Rheumocam

Active Ingredient:: Meloxicam
Brand:: Rheumocam
Origin:: European Union

Rheumocam (Meloxicam)

Meloxicam, the active ingredient in Rheumocam, is a nonsteroidal anti-inflammatory drug presented as a tablet for oral use. It reduces inflammation and pain associated with osteoarthritis, rheumatoid arthritis and other musculoskeletal conditions in adult patients, providing symptomatic relief and improved joint function.

GNH India supplies Rheumocam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution originating from the European Union market. The company adheres to stringent quality standards and regulatory requirements.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Meloxicam is an NSAID indicated for several inflammatory joint disorders.

Osteoarthritis: alleviates joint pain and stiffness, improving mobility.
Rheumatoid arthritis: reduces synovial inflammation and pain, helping preserve joint function.
Musculoskeletal pain: provides analgesic relief for acute or chronic soft‑tissue pain.

How It Works

Meloxicam exerts its anti‑inflammatory and analgesic actions by reversibly inhibiting cyclooxygenase‑1 (COX‑1) and cyclooxygenase‑2 (COX‑2) enzymes. This inhibition decreases the conversion of arachidonic acid to prostaglandins, which are mediators of inflammation, pain and fever. By lowering prostaglandin synthesis, meloxicam diminishes inflammatory responses in affected tissues.

Side Effects

Meloxicam may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

Gastrointestinal discomfort: nausea, dyspepsia or abdominal pain.
Headache: mild to moderate intensity.
Dizziness or vertigo.
Peripheral edema: swelling of the lower limbs.
Skin rash: mild erythema or itching.

Serious or Rare Side Effects

Peptic ulcer disease or gastrointestinal bleeding.
Severe hepatic injury: jaundice or elevated liver enzymes.
Renal impairment: reduced urine output or increased creatinine.
Cardiovascular events: hypertension, myocardial infarction or stroke.
Anaphylactic reactions: difficulty breathing, swelling of face or throat.

Precautions & Warnings

Before prescribing meloxicam, clinicians should consider several safety precautions to minimise risk.

Assess renal function: avoid use in patients with severe renal impairment.
Evaluate hepatic status: monitor liver enzymes in those with liver disease.
Cardiovascular risk: use cautiously in patients with hypertension, heart failure or prior thrombotic events.
Gastrointestinal history: avoid in individuals with active ulcer disease or a history of GI bleeding.
Concomitant NSAIDs or anticoagulants: increase bleeding risk, consider alternatives.
Store at room temperature: keep below 25 °C, retain in original packaging and protect from moisture.

Avoid Interactions

Meloxicam can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

Anticoagulants (e.g., warfarin): increased risk of serious bleeding.
Other NSAIDs or COX‑2 inhibitors: heightened gastrointestinal toxicity.
Selective serotonin reuptake inhibitors (SSRIs): elevated bleeding potential.

Moderate Interactions (Monitor Closely)

ACE inhibitors or diuretics: may reduce renal function.
Lithium: meloxicam can raise lithium serum levels.
Methotrexate: potential for increased toxicity.
Corticosteroids: additive risk of GI ulceration.

Frequently Asked Questions

Rheumocam contains meloxicam, an NSAID prescribed to relieve pain and inflammation in conditions such as osteoarthritis, rheumatoid arthritis and other musculoskeletal disorders. It helps improve joint function and reduces discomfort in adult patients.

Meloxicam works by reversibly inhibiting the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which are essential for converting arachidonic acid into prostaglandins. By lowering prostaglandin levels, it diminishes the inflammatory response, pain perception and fever associated with joint disease.

The appropriate dose of Rheumocam is determined by the prescribing clinician based on the patient’s condition, severity, age, renal and hepatic function, and other individual factors. Only a qualified health professional should set the dosing regimen.

Meloxicam is generally not recommended during pregnancy, especially in the third trimester, because of potential risks to the fetus. Limited data exist for breastfeeding, and the drug may pass into breast milk; therefore, use should be avoided unless clearly needed and approved by a physician.

To request Rheumocam, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and the necessary import documentation.

Rheumocam (meloxicam) offers a longer half‑life than many traditional NSAIDs, allowing once‑daily dosing for many patients. It provides a balanced inhibition of COX‑1 and COX‑2, which can result in comparable analgesic efficacy with a potentially lower gastrointestinal risk than non‑selective NSAIDs, though individual response varies.

Rheumocam tablets should be stored at room temperature, below 25 °C, in their original blister or bottle. Keep the product away from moisture, direct sunlight and heat sources to maintain stability and potency throughout its shelf life.

Rheumocam is taken orally, usually with a full glass of water. It may be taken with or without food, but patients who experience stomach upset are often advised to take it with meals. The exact administration schedule is set by the prescribing clinician.

Serious risks include gastrointestinal bleeding or ulceration, severe liver injury, kidney impairment, cardiovascular events such as heart attack or stroke, and rare but life‑threatening allergic reactions (anaphylaxis). Patients should seek immediate medical attention if they notice signs such black stools, jaundice, sudden swelling, or difficulty breathing.

Rheumocam should be avoided in patients with known hypersensitivity to meloxicam or other NSAIDs, active peptic ulcer disease, severe renal or hepatic impairment, uncontrolled hypertension, and those who have experienced recent cardiovascular events. It is also contraindicated during late pregnancy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Rheumocam (Meloxicam)

Indications & Clinical Uses

How It Works